Positive Phase IV ElectroChemotherapy Clinical Data

2011 has been a resounding success for OncoSec, and 2012 is shaping up to be a pivotal year. Over this last year OncoSec has established a robust clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy treatment platform for the treatment of rare and deadly skin cancers, including (1) metastatic melanoma; (2) Merkel cell carcinoma; and (3) cutaneous T-cell lymphoma. In conjunction, the company has continued to create value from its advanced-stage OMS ElectroChemotherapy program for the treatment of [...More...]

A High-Tech Battle Against a Deadly Cancer

Right now, University of Washington researchers are engaged in a potentially life-saving quest: the world’s first clinical trial using electroporation in immunotherapy that’s specifically targeting Merkel cell carcinoma. This is a rare and highly aggressive form of skin cancer with a 40% mortality rate and about 1,500 new cases each year. Last week, OncoSec was featured in a news segment by a local NBC affiliate in Seattle, WA, KIRO News 7, that told the story of the great [...More...]

A Letter to Our Shareholders

NUMBERS ARE ONLY PART OF THE STORY
Numbers are important. They can be compared against others and tell us how far we have come and how far we have to go. Numbers help us measure our goals and aspirations, and show the world how we intend to reach them. They estimate odds and probabilities and they calculate results. They are necessarily impartial, rational and dispassionate.

But numbers only tell half the story.

They will never be able to put a value on the [...More...]

OncoSec Revolutionizing Targeted Cancer Therapy

OncoSec – Positive Phase IV ElectroChemotherapy Clinical Data

OncoSec has continued to demonstrate a commitment to achieving our corporate milestones and confirming the company’s urgency for developing revolutionary targeted therapies using its proprietary electroporation delivery system, the OncoSec Medical System, or OMS. With our recent $7.75 million financing we are now poised to focus our resources on exceeding expectations and continuing to drive value from our novel OMS treatment platforms.

OMS ElectroChemotherapy: Targeted Ablation of Solid Tumor Cancers

Today, we announced positive data [...More...]

Join us on the Ride to Conquer Cancer

Dear family and friends:

In the past few years, I’ve decided to invest myself in a number of things that have consequently… changed my life. The first involvement came in the form of a marathon, and then another, followed by my first iron man competition. The second was in the founding of OncoSec Medical in March 2011, a biomedical company dedicated to advancing novel technology in treating solid tumors.

Before OncoSec was formed, I wasn’t ready for the intensely detrimental and impactful [...More...]

Why Participate in Social-Digital Now?

Punit Dhillon, President & CEO

Every day over 1,500 people in the US and an estimated 20,000 people around the world, just like you and me, will hear the news that they have been diagnosed with cancer. Thousands of them will be in the indication of melanoma or another lethal form of cancer. Those diagnosed with late stage cancer that has metastasized, or spread to other parts of the body, will have to face the difficult fact that there is less [...More...]